Priyanka Bobbili

Education

Sc.D. and M.S., epidemiology, Harvard T.H. Chan School of Public Health; B.S., chemical and biological engineering, Massachusetts Institute of Technology

Summary of Experience

Dr. Bobbili specializes in the application of statistical methods to the causal analysis of complex longitudinal data. She has a wide range of experience in epidemiology and health economics and outcomes research (HEOR), including studies on causal methods, drug adherence, and comparative effectiveness, particularly in the oncology disease area. Dr. Bobbili has experience designing and conducting studies using large, observational, and real-world data sources to emulate target trials. She has been involved in several studies to support US Food and Drug Administration (FDA) new drug applications (NDAs) and supplemental new drug applications (sNDAs), particularly real-world historical control studies to contextualize the results of clinical trials. Her work has been presented at multiple conferences and published in numerous peer-reviewed journals. Prior to joining Analysis Group, Dr. Bobbili served as a research assistant and teaching assistant at the Harvard T. H. Chan School of Public Health.

Read Priyanka's profile

Selected Publishing

• Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

  Leukemia, 2022
  2022

  Reiter A, Gotlib J, Álvarez-Twose I, Radia DH, Lübke J, Bobbili PJ, Wang A, Norregaard C, Dimitrijevic S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky IA, Perkins C, Sperr WR, Sriskandarajah P, Chin A, Sendhil SR, Duh MS, Valent P, DeAngelo DJ

  HEOR, Epidemiology & Market Access
• MPN-435 Overall Survival in Patients With Systemic Mastocytosis With Associated Hematologic Neoplasm Treated With Avapritinib Versus Best Available Therapy

  Clinical Lymphoma, Myeloma & Leukemia, 2022
  2022

  Reiter A, Gotlib J, Álvarez-Twose I, Radia D, Lübke J, Bobbili P, Wang A, Norregaard C, Dimitrijević S, Sullivan E, Louie-Gao M, Schwaab J, Galinsky I, Perkins C, Sperr W, Sriskandarajah P, Chin A, Sendhil S, Duh MS, Valent P, DeAngelo D

  HEOR, Epidemiology & Market Access
• Long-Term Effectiveness and Safety of Dutasteride versus Finasteride in Patients with Male Androgenic Alopecia in South Korea: A Multicentre Chart Review Study

  Annals of Dermatology, 2022
  2022

  Choi GS, Sim WY, Kang H, Huh CH, Lee YW, Shantakumar S, Ho YF, Oh EJ, Duh MS, Cheng WY, Bobbili P, Thompson-Leduc P, Ong G

  HEOR, Epidemiology & Market Access
• Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer

  PLOS One, 2020
  2020

  Bobbili P, Ryan K, DerSarkissian M, Dua A, Yee C, Duh MS, Gomez JE

  HEOR, Epidemiology & Market Access
• Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study

  Hereditary Cancer in Clinical Practice, 2020
  2020

  Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N

  HEOR, Epidemiology & Market Access
• Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma

  Cancer, 2020
  2020

  Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD

  HEOR, Epidemiology & Market Access
• Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis

  American Journal of Hematology, 2019
  2019

  Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB

  HEOR, Epidemiology & Market Access
• Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer

  Future Oncology, 2019
  2019

  Bobbili P, Ryan K, Duh MS, Dua A, Fernandes AW, Pavilack M, Gomez JE

  HEOR, Epidemiology & Market Access
• Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans

  Clinical Therapeutics. 2018 Sep;40(9):1496-1508
  2018

  DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y

  HEOR, Epidemiology & Market Access
• Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets

  Current Medical Research and Opinion. Apr 27 2018:1-14
  2018

  Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M 

Events

• August 24, 2019

  Analysis Group to Present at ICPE 2019

  Event: 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
  Host: The International Society for Pharmacoepidemiology (ISPE)

• August 24, 2021

  Analysis Group Research Featured in Spotlight Poster at ICPE 2021

  Event: 37th International Conference on Pharmacoepidemiology (ICPE)
  Host: International Society for Pharmacoepidemiology

News

• August 17, 2022

  Analysis Group Announces Real-World Evidence Study Supported Blueprint Medicines’ Label Expansion of AYVAKYT® (avapritinib) to Advanced Systemic Mastocytosis in the EU

  HEOR, Epidemiology & Market Access